Louisville, KY, United States of America

Paula J Bates

This inventor holds 18 USPTO granted patents and 9 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: University Of Louisville Research Foundation, Inc., Advanced Cancer Therapeutics, LLC, Antisoma Research Limited. Active years: 2008-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paula J Bates. Retrieved from https://idiyas.com/inventor/paula-j-bates

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 9)

% Patents Active = 61.1

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 75(Granted Patents)

Company Filing History:

14 out of 398

University Of Louisville Research Foundation, Inc.

patents

3 out of 7

Advanced Cancer Therapeutics, LLC

patents

1 out of 4

Antisoma Research Limited

patents

Years Active: 2008-2023

Loading Chart...

Areas of Expertise:

Anti-Nucleolin Agents

Nanoparticles

DNMT1 Inhibitors

Therapeutic Compounds

MRI Contrast Agents

Oligonucleotides

Malignant Diseases

Predictive Markers

Radio-Sensitizers

Pharmaceutical Compositions

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11679098 - Methods for treating diseases (2023-06-20),

2. 11344633 - Anti-nucleolin agent-conjugated nanoparticles (2022-05-31),

3. 11208379 - Compounds, compositions, methods for treating diseases, and methods for preparing compounds (2021-12-28),

4. 10857237 - Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents (2020-12-08),

5. 9737493 - Compositions and methods for modulating DNMT1 inhibitor activity (2017-08-22),

6. 9492428 - Compounds, compositions, pharmaceutical compositions, and methods of use (2016-11-15),

7. 9452219 - Anti-nucleolin agent-conjugated nanoparticles (2016-09-27),

8. 9383364 - Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker (2016-07-05),

9. 8703829 - Therapeutic compounds (2014-04-22),

10. 8648051 - Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin (2014-02-11),

11. 8586717 - Method for the diagnosis and prognosis of malignant diseases (2013-11-19),

12. 8207381 - Therapeutic compounds (2012-06-26),

13. 8114850 - Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin (2012-02-14),

14. 8029784 - Method for the diagnosis and prognosis of malignant diseases (2011-10-04),

15. 7960540 - Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin (2011-06-14),

Title: The Innovative Contributions of Paula J Bates: A Trailblazer in Cancer Treatment

Introduction: Paula J Bates, based in Louisville, KY, is a notable inventor with an impressive portfolio of 18 patents. Her work primarily focuses on advancing treatment methodologies for diseases, particularly in the field of cancer. With a commitment to innovation, Bates has contributed significantly to the medical community through her inventions.

Latest Patents: Among Paula J Bates's latest patents are methods for treating diseases, which include the use of specific compounds, such as Formula (I), Formula (II), or I-1. These methods target particularly challenging forms of cancer, including chemo-resistant and cancer-therapy-resistant variants. Additionally, she has developed a patent for anti-nucleolin agent-conjugated nanoparticles. This innovative composition links an anti-nucleolin agent to non-magnetic nanoparticles, providing a pharmaceutical composition designed for effective cancer treatment alongside a pharmaceutically acceptable carrier.

Career Highlights: Throughout her career, Paula J Bates has worked with prominent organizations such as the University of Louisville Research Foundation and Advanced Cancer Therapeutics. Her experience in these institutions has allowed her to shape her research and innovations, leading to significant advancements in cancer therapies.

Collaborations: Paula has collaborated with esteemed professionals in the field, including Donald Miller and John Olaf Trent. These partnerships have enriched her work and facilitated the development of groundbreaking treatments.

Conclusion: Paula J Bates exemplifies the spirit of innovation within the healthcare sector. Her dedication to improving cancer treatments through her patents underscores the vital role inventors play in advancing medical science. As her work continues to evolve, it is anticipated that she will remain a key figure in the ongoing fight against cancer.

Profile summary based on public USPTO records.